Bausch + Lomb is executing a turnaround characterized by accelerating revenue growth (8.7% YoY in 2026Q2) and gross margin expansion to 59.1%, driven by improved product mix and disciplined SG&A control. Operating leverage is emerging, with operating income sw...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 8.7% YoY in 2026Q2 with gross margin expanding to 59.1% from 53.7% a year earlier, though net losses persist at -$10M for the quarter.
Bausch + Lomb delivered a solid 9% YoY revenue growth to $1.24B in Q1 2026, indicating robust business performance.
Adjusted EBITDA Excluding Acquired IPR&D surged 59% YoY to $200M, showcasing significant operational leverage.
The company demonstrated that promised FY25 structural margin improvements are flowing to the bottom line in Q1 2026.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $0.16+3.6% vs $0.15 | $1.4B+1.8% vs $1.4B |
Q2 2026 Apr 29, 2026 | $0.08+33.3% vs $0.06 | $1.2B+2.3% vs $1.2B |
Q1 2026 Feb 18, 2026 | $0.32-8.6% vs $0.35 | $1.4B+1.4% vs $1.4B |
Q4 2025 Oct 29, 2025 | $0.18+12.5% vs $0.16 | $1.3B-7.4% vs $1.4B |
Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company's next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for premium cataract, LASIK flap and corneal therapeutic surgeries while simultaneously.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered both good distance and functional intermediate vision, thus meeting.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around dry eye and its association with perimenopause and menopause. The survey found that dry eye remains one of the least recognized symptoms experienced during these stages of life. According to the survey, only 14% of peri-, menopausal and p.
Benchmark BLCO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bausch + Lomb Corporation (BLCO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.05 | $6.09B | -16.72 | 6.47% | -7.06% | -5.51% | — | |
| $85.05 | $9.69B | 26.01 | 4.03% | 2.96% | 8.38% | — | |
| $59.96 | $3.05B | -249.81 | 14.88% | 1.85% | 2.14% | — | |
| $99.97 | $6.51B | 29.32 | 0.5% | 17.69% | 23.27% | — | |
| $269.17 | $647.95B | 24.40 | 6.05% | 21.58% | 25.75% | — | |
| $103.53 | $180.32B | 27.83 | 5.67% | 13.91% | 12.09% | — |
Bausch + Lomb Corporation (BLCO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bausch + Lomb Corporation (BLCO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
May 20, 2026·SEC
Apr 29, 2026·SEC
Get notified when BLCO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bausch + Lomb Corporation (BLCO) stock FAQ — growth, dividends, profitability & financials explained
Bausch + Lomb Corporation (BLCO) reported $5.32B in revenue for fiscal year 2025. This represents a 41% increase from $3.78B in 2019.
Bausch + Lomb Corporation (BLCO) grew revenue by 6.5% over the past year. This is steady growth.
Bausch + Lomb Corporation (BLCO) reported a net loss of $167.0M for fiscal year 2025.
Bausch + Lomb Corporation (BLCO) has a return on equity (ROE) of -5.5%. Negative ROE indicates the company is unprofitable.
Bausch + Lomb Corporation (BLCO) generated $140.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
